Abstract: Substituted phenyl and naphthyl and 9-oxofluoren-4-yl esters of PGF.sub.2 .alpha., 15-alkyl-PGF.sub.2 .alpha., and 15(R)-15-alkyl-PGF.sub.2 .alpha., and their recemic forms, and processes for producing them are disclosed. The products are useful for the same pharamacological and medical purposes as PGF.sub.2 .alpha., 15-alkyl-PGF.sub.2 .alpha., and 15(R)-15-alkyl-PGF.sub.2 .alpha., and are also useful as a means for obtaining highly purified PGF.sub.2 .alpha., 15-alkyl-PGF.sub.2 .alpha., and 15(R)-15-alkyl-PGF.sub.2 .alpha. products.

Abstract: This invention is a group of 4,5-didehydro and 4,5,17,18-tetradehydro PG.sub.1 (prostaglandin-type) compounds, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

Abstract: Prostaglandin F.sub.2 -type compounds with one or two methyl or ethyl substituents at the C-16 position are disclosed. These are useful for the same pharmacological purposes as the unsubstituted prostaglandins.

Abstract: Prostaglandin E.sub.1 -type, F.sub.1 -type, A.sub.1 -type, and B.sub.1 -type compounds with one or two methyl or ethyl substituents at the C-16 position are disclosed. These are useful for the same pharmacological purposes as the unsubstituted prostaglandins.

Abstract: Tricyclic lactone glycol sulfonates of the formula ##SPC1##Or ##SPC2##Wherein R.sub.3 is alkyl of one to 10 carbon atoms, inclusive, aralkyl of 7 to 12 carbon atoms, inclusive, phenyl, or phenyl substituted with one or 2 halo or alkyl of one to 4 carbon atoms, inclusive;Wherein R.sub.4 is alkyl of one to 10 carbon atoms, inclusive, aralkyl of 7 to 12 carbon atoms, inclusive, phenyl, or phenyl substituted with one or 2 halo or alkyl of one to 4 carbon atoms, inclusive; andWherein W is 1-pentyl, 1-pent-cis-2-enyl, or 1-pent-2-ynyl.These compounds are useful in preparing stereo-specifically prostaglandins having pharmacological utility.

Abstract: Substituted anilide esters of PGA.sub.1, 15-alkyl-PGA.sub.1, and 15(R)-15-alkyl-PGA.sub.1, and their racemic forms, and processes for producing them are disclosed. The products are useful for the same pharmacological and medical purposes as PGA.sub.1, 15-alkyl-PGA.sub.1, and 15(R)-15-alkyl-PGA.sub.1, and are also useful as a means for obtaining highly purified PGA.sub.1, 15-alkyl-PGA.sub.1, and 15(R)-15-alkyl-PGA.sub.1 products.

Abstract: Novel methods are disclosed for transforming PGA.sub.2 and 15.beta.-PGA.sub.2 and their acetates, methyl esters, and acetate methyl esters to various prostanoic acids and esters of the PGE.sub.2 and PGF.sub.2.sub..alpha. series. Some of the latter are novel and are useful for the same pharmacological purposes as PGE.sub.2 and PGF.sub.2.sub..alpha..

Abstract: Substituted tolyl esters of PGA.sub.1, 15-alkyl-PGA.sub.1, and 15(R)-15-alkyl-PGA.sub.1, and their racemic forms, and processes for producing them are disclosed. The products are useful for the same pharmacological and medical purposes as PGA.sub.1, 15-alkyl-PGA.sub.1, and 15(R)-15-alkyl-PGA.sub.1, and are also useful as a means for obtaining highly purified PGA.sub.1, 15-alkyl-PGA.sub.1, and 15(R)-15-alkyl-PGA.sub.1 products.

Abstract: Process for resolving a racemic mixture of an oxo-type prostaglandin intermediate by (a) converting the oxo compound by reaction with an optically active ephedrine to a mixture of oxazolidine diastereomers, (b) separating at least one oxazolidine diastereomer from said mixture, (c) hydrolyzing said oxazolidine to free the optically active oxo compound, and (d) recovering said optically active oxo compound.

Abstract: This invention is a group of PGF.sub.1.sub..alpha. -type oxaphenylene compounds, and processes for making them. These compounds are useful for a variety of pharamcological purposes, including inhibition of platelet aggregation, treatment of asthma, labor inducement at term, and cervical dilation.

Abstract: This invention is a group of 3-oxa PGE-type compounds, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including antiulcer, inhibition and platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

Abstract: This invention is a group of 3- and 4-oxa PG type compounds, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

Abstract: This invention is a group of PGA.sub.1 -type oxa-phenylene compounds, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, treatment of asthma, and management of renal dysfuction.

Abstract: Novel methods are disclosed for transforming PGA.sub.2 and 15.beta.-PGA.sub.2 and their acetates, methyl esters, and acetate methyl esters to various prostanoic acids and esters of the PGE.sub.2 and PGF.sub.2.sub..alpha. series. Some of the latter are novel and are useful for the same pharmacological purposes as PGE.sub.2 and PGF.sub.2.sub..alpha..

Abstract: This invention is a group of PGF.sub.1.sub..beta. -type and PGF.sub.2.sub..beta. -type oxa-phenylene compounds, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including inhibition of platelet aggregation, treatment of asthma, labor inducement at term, and cervical dilation.

Abstract: This invention is a group of PGE.sub.1 -type oxa-phenylene compounds, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

Abstract: This invention is a group of 4,5-didehydro PG.sub.1 (prostaglandin-type) analogs having variable chain length, branching and fluoro substitution in the hydroxy-substituted side-chain, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

Abstract: This invention is a group of 17,18-didehydro-PG.sub.1 - and -PG.sub.2 -type oxa-phenylene compounds, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

Abstract: This invention is a group of 13,14-dihydro-PGE.sub.1 -type (also referred to as PGE.sub.o -type) oxa-phenylene compounds, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

Abstract: This invention is a group of PGE.sub.2 -type oxa-phenylene compounds, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.